INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Results

82,053 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
CT
Chuang Patrick T.Senior VP, Memory Design
GSITGSI TECHNOLOGY INC
Grant or award
A—
20.0K sh
Feb 2, 2026Feb 4, 2026
Page 1617 of 2052
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$11K
111 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
TA
Thompson Travis AlvinChief Financial Officer
BCYCBICYCLE THERAPEUTICS PLC
Grant or award
A—
58.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Grant or award
A—
4,342 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NP
Naude PierreDirector
NCNOnCino, Inc.
Grant or award
A—
3,516 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
RG
Russotti GregorySee Remarks
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$30K
2,797 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

3
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,700 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
15.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,742 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M$73K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

2
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
6,017 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$1,398
556 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

1
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$75K
381 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
SN
Sieffert Kristen NPresident
FOAFinance of America Companies Inc.
Open-market sale · 10b5-1 plan
SELL$17K
750 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

1
BM
Barrett David MichaelDirector, Chief Executive Officer
EXFYExpensify, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
30.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
FA
Fang AndyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
TS
Tang StanleyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
45.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$7,449
39 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
KW
Kozarich John WDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$4,499
23 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Option exercise · 10b5-1 plan
M—
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M$2,800
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
FA
Fang AndyDirector
DASHDoorDash, Inc.
Other acquisition or disposition · 10b5-1 plan
J—
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
WS
Wampler Kira SchererDirector
DOCSDoximity, Inc.
Derivative conversion · 10b5-1 plan
C—
2,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

0
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence